Effect of Beta-Blockers on Progressive Aortic Dilatation in Patients with Marfan Syndrome

Parasuram Krishnamoorthy MD

Jalaj Garg MD
Lehigh Valley Health Network, jalaj.garg@lvhn.org

Neeraj Shah MD
Lehigh Valley Health Network, Neeraj_N.Shah@lvhn.org

Abhishek Sharma MD

Larry E. Jacobs MD
Lehigh Valley Health Network, larry.jacobs@lvhn.org

See next page for additional authors

Follow this and additional works at: https://scholarlyworks.lvhn.org/medicine
Part of the Cardiology Commons, and the Medical Sciences Commons

Published In/Presented At

This Poster is brought to you for free and open access by LVHN Scholarly Works. It has been accepted for inclusion in LVHN Scholarly Works by an authorized administrator. For more information, please contact LibraryServices@lvhn.org.
Effect of Beta-Blockers on Progressive Aortic Dilatation in Patients with Marfan Syndrome

Parasuram Krishnamoorthy,1 Jalaj Garg,2 Neeraj Shah,2 Abhishek Sharma,3 Larry Jacobs,2 Matthew Martinez2
1Englewood Hospital and Medical Center; 2Lehigh Valley Health Network; 3State University of New York Downstate Medical Center

BACKGROUND

• Marfan syndrome is a multi-systemic connective tissue disorder caused by a fibrillin-1 mutation. The objective of our study was to determine the effect of beta-blockers on aortic dilatation progression in patients with Marfan syndrome.

METHODS

• We performed a systematic review of all prospective trials that evaluated the efficacy of beta-blockers in patients with Marfan syndrome.

• Primary outcome of the study included echocardiographic measures of aortic root at sinus of valsalva in patients treated and untreated with beta-blockers.

• Secondary outcomes included mortality, aortic dissection, and surgical repair between the two groups.

RESULTS

• Four prospective trials were identified with comparable groups, 174 patients were included for analysis. Mean age was 10.6 years.

• Compared to control (non beta-blocker group), beta-blockers significantly decreased the rate of aortic dilatation (OR -0.88, 95% CI -1.26– -0.51, p <0.001).

• However, the final aortic size was the same despite the use of beta-blocker.

CONCLUSION

Interestingly, there was also no statistical significant difference in secondary outcome in the beta-blocker group when compared with no beta-blocker treatment group (OR = 5.88, 95% CI 0.70-49.26).

This meta-analysis demonstrates that although beta-blockers were effective in aortic root growth rate reduction in patients with Marfan syndrome, the secondary outcomes i.e. the rate of dissection and final aortic size were the same regardless of beta-blocker usage.

Disclosure: P Krishnamoorthy: None; J Garg: None; N Shah: None; A Sharma: None; L Jacobs: None; M Martinez: None.